Asensus Surgical (ASXC) Stock Forecast & Price Target
Asensus Surgical (ASXC) Analyst Ratings
Bulls say
Asensus Surgical Inc. demonstrates a robust outlook due to the significant growth of surgical procedures, with over 3,550 performed in 2023, reflecting a 13% year-over-year increase. The company's investments in research and development, amounting to $9.3 million and a 39% increase year-over-year, indicate a commitment to innovation and long-term growth potential through new product offerings like LUNA and the Intelligent Surgical Unit. Additionally, the anticipated expansion of the Senhance programs in 2024, along with the projected 15%-20% growth in procedure volume, highlights a favorable market positioning within a substantial $56 billion global opportunity in laparoscopic surgeries.
Bears say
Asensus Surgical Inc reported total revenues of $5.4 million for 4Q23, slightly below the consensus estimate of $5.5 million, and experienced a net loss of $0.07 per share, conforming to expectations, which highlights challenges in meeting growth targets. The company revised its Senhance placements guidance down to 8-10 units for 2023, signaling potential struggles in market penetration and product adoption, particularly amidst a tough economic environment and increasing competition in the surgical robotics sector. Additionally, the significant reduction in revenue estimates to $6.8 million from $8.0 million, compounded by concerns over liquidity and a lack of visibility into the company's future financial performance, supports a cautious outlook.
This aggregate rating is based on analysts' research of Asensus Surgical and is not a guaranteed prediction by Public.com or investment advice.
Asensus Surgical (ASXC) Analyst Forecast & Price Prediction
Start investing in Asensus Surgical (ASXC)
Order type
Buy in
Order amount
Est. shares
0 shares